Rosiglitazone and not fenofibrate treatment decreases atherogenesis in obese, insulin resistant mice.

<p>(<b>A</b>) Representative Mac-3 staining of aortic sinus plaques of placebo-, fenofibrate- and rosiglitazone-treated DKO mice at 24 weeks. (<b>B</b>) Gene expression in the aorta was analyzed by measuring relative <i>RNA</i> levels using qRT-PCR for <i>Tnfα</i>, <i>IL6</i>, <i>Mcp1</i> and <i>Irak3</i>. Data are means ± SEM. Scale bar = 500 µm. *<i>P</i><0.05, **<i>P</i><0.01 and ***<i>P</i><0.001 DKO compared with C57BL/6 J mice; ^$$<i>P</i><0.01 and ^$$$<i>P</i><0.001 PPAR agonist-treated compared with placebo-treated DKO mice; ^£<i>P</i><0.05, ^££<i>P</i><0.01 and ^£££<i>P</i><0.001 rosiglitazone-treated compared with fenofibrate-treated DKO mice.